Trastuzumab deruxtecan recommended in NICE draft guidance for use in the CDF for breast cancer after two or more anti-HER2 therapies
More data from trials and NHS practice are needed to help address the uncertainty about clinical effectiveness.
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date